Floatz logo

Zoledronate

Multiple System Atrophy

California Pacific Medical Center Research InstituteSmall moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

27 Active assets in the Multiple System Atrophy cohort.

Asset / SponsorPhaseRating
Droxidopa
Loma Linda University
Phase 3BB
ATH-434
Alterity Therapeutics
Phase 2B
IOFLUPANE
GE Healthcare
Phase 3B
Riluzole
King's College London
Phase 3B
Exidavnemab
BioArctic AB
Phase 2CCC

View all 40 →

Same molecule, other indications

Zoledronate is also rated in:

metastatic carcinoma in the boneDormant
BBB
Indicative ·
79 / 100
View asset →
osteoporosisDormant
BBB
Indicative ·
76 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →